The Omnipod 5 System: Trial Results From ENDO 2021

This transcript has been edited for clarity.

I was incredibly excited to see the results of the Omnipod 5, also known as the Horizon, trial at the Endocrine Society meeting. Many of my patients and I have been waiting for this technology to become available. It's not yet approved by the US Food and Drug Administration (FDA), but at least we have the trial results.

So what is the Omnipod 5 system? There are three components: the Omnipod tubeless insulin pump, the Dexcom G6 continuous glucose monitor (CGM), and the Omnipod control algorithm. This system can be completely controlled from an individual's smartphone, but it has to be an Android phone. If someone doesn't have an Android phone, then they're given a locked Android phone for the purpose of controlling this system.

Basically, it's a hybrid closed-loop system. But the key here is that it uses the Omnipod, so patients don't have to use a tethered pump. This is a different system.

What I really like about it is that unlike other systems that are similar, it has customizable targets so people can change the targets between 110 and 150 mg/dL. So, if you have a patient whose glucose levels is higher coming into this, you may not want to use such a low target as 120 or 110 mg/dL.